Hormone Therapy Reimagined2.pdf

Over 1 million U.S. women enter menopause each year and yet few are offered evidence-based hormonal support for long-term brain, bone, and cardiovascular health. Despite emerging evidence, most guidelines continue to group all estrogens and progestogens into the same risk category. But not all hormones are created equal. Much of the caution surrounding menopausal hormone therapy (MHT) stems from early interpretations of the Women’s Health Initiative (WHI) studies. But as science evolves, so should our treatment guidelines. This article provides a comprehensive analysis of the reasoning behind current entrenched guidelines, an update of evidence on the systemic benefits and minimal risks of bioidentical hormone formulations. <br>